Need for a paradigm shift: The importance of risk factor reduction therapy in treating patients with cardiovascular disease

被引:0
|
作者
Smith, SC
机构
[1] Univ N Carolina, Div Cardiol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Acad Ctr Cardiovasc Dis, Chapel Hill, NC 27599 USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 1998年 / 82卷 / 10B期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease remains the number one killer in the United States, despite advances made in diagnosis and therapy. A major shift to expand treatment beyond symptomatic obstructions and infarctions toward comprehensive therapies aimed at treatment of the underlying disease process could decrease the death rate and cost of cardiovascular disease enormously. In the past 5 years, major trials have clearly demonstrated that aggressive intervention with lipid-lowering therapy can dramatically alter the course of disease. Aspirin, smoking cessation, exercise, diet, and other medical and lifestyle interventions can also decrease risk. Successful therapies are not being implemented, however. Making prevention the primary approach to treatment will require increased resource allocation, use of health provider teams, integration of healthcare delivery systems, and expanded emphasis on educating patients about prevention. (C) 1998 by Excerpta Medica, Inc.
引用
收藏
页码:10T / 13T
页数:4
相关论文
共 50 条
  • [21] Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia
    Courtney D. Thornburg
    Dana H. Simmons
    Annette von Drygalski
    BioDrugs, 2023, 37 : 595 - 606
  • [22] Implementing Cardiovascular Risk Reduction in Patients with Cardiovascular Disease and Diabetes Mellitus
    Nandish, Shailesh
    Wyatt, Jamison
    Bailon, Oscar
    Smith, Mike
    Oliveros, Rene
    Chilton, Robert
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (03): : 42B - 51B
  • [23] Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia
    Thornburg, Courtney D.
    Simmons, Dana H.
    von Drygalski, Annette
    BIODRUGS, 2023, 37 (05) : 595 - 606
  • [24] Integrated programmes for cardiovascular disease risk reduction: the need for new models of care
    Ofori, Sandra N.
    HEART, 2017, 103 (11) : 805 - 806
  • [25] Central aortic blood pressure and cardiovascular risk - A paradigm shift?
    Avolio, Alberto
    HYPERTENSION, 2008, 51 (06) : 1470 - 1471
  • [26] The highs and lows of cardiovascular risk prediction: Time for paradigm shift?
    Joshi, Parag H.
    Nasir, Khurram
    ATHEROSCLEROSIS, 2015, 239 (02) : 436 - 438
  • [27] Cardiovascular disease as a risk factor for frailty in dialysis patients
    Tong, Kah Cheong
    Wee, Khui Wei
    KIDNEY INTERNATIONAL, 2024, 106 (03) : 537 - 538
  • [28] Hyperhomocysteinemia in hemodialysis patients: Is it a risk factor for cardiovascular disease?
    Vecchi, ML
    Di Lorenzo, G
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2005, 28 (03): : 207 - 210
  • [29] Importance of smoking cessation for cardiovascular risk reduction
    Moller, Amalie Lykkemark
    Andersson, Charlotte
    EUROPEAN HEART JOURNAL, 2021, 42 (40) : 4154 - 4156
  • [30] Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
    Gouni-Berthold, Ioanna
    Berthold, Heiner K.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (31) : 5025 - 5038